Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS - ULR 7369)
Loos, 59120, France
NCT Number: NCT07365176
This randomized crossover trial examined whether exercise modality (high-intensity interval exercise vs. moderate-intensity continuous exercise) and timing relative to meals (postprandial vs. postabsorptive) influence glycemic responses in physically active adults with type 1 diabetes. Participants completed four cycling sessions matched for total mechanical load, and glucose levels were monitored during exercise and for 24 hours afterward while accounting for dietary intake and insulin administration. The study hypothesized that glycemic responses differ according to both exercise type and prandial state.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Loos, 59120, France
Participants were tested at the laboratory during one inclusion visit followed by 4 intervention visits separated by at least 48 hours and 4 weeks maximum. During the inclusion visit, participants completed the YMCA submaximal cycle-ergometer (Excalibur Sport, Lode B.V.) test to estimate maximal aerobic power (MAP), which was then used to determine subsequent exercise workloads. The test started at 25 W (50 rpm), with increasing power outputs derived from the first-stage heart-rate response. The 3-min stages continued until steady-state heart rate achieved 85% of maximal heart rate minus 10 bpm, with a 1-min extension if heart rate varied by >5 beats·min-¹ between minutes 2 and 3. Participants completed questionnaires about physical activity levels, barriers to physical activity, quality-of-life and hypoglycemia awareness. The next four experimental visits in randomized order consisted of the two aerobic exercises (i.e. high-intensity interval exercise, HIIE and moderate-intensity continuous exercise, CONT), each performed under two different prandial conditions, postprandial (PP) and postabsorptive (PA) state. A triaxial accelerometer (ActiGraph, wGT3X-BT, 30 Hz, epoch set at 60 sec) was worn on the hip from wake-up until bedtime for the day before, during and after each experimental visit. Participants were also asked to record the time, type and amount of food consumed, with the option of photographing meals, as well as in case of multiple daily injection doses/timing of insulin (rapid- and long-acting), the 24 hours before, during and after each visit. Exercises were performed on a cycle ergometer (Excalibur Sport, Lode B.V.) and were matched for total mechanical load and total duration. Both exercises began with a 3-min warm-up at 20% of MAP and ended with a 2-min active recovery at 20% of MAP. The HIIE protocol consisted of ten 1-min intervals at 100% of MAP, each interspersed with 1-min of passive recovery. The CONT protocol consisted of continuous exercise at 50% of MAP for 20 minutes. For the postprandial state, exercise began 1.5 hours after the start of lunch and the corresponding meal-related bolus/rapid-acting insulin, (i.e., in the early afternoon). For the postabsorptive state, exercise began 5 hours after the start of lunch, (i.e., in the late afternoon). Participants were instructed to follow their habitual pre-exercise routine and to replicate, as closely as possible, the same lunch and dinner on the days of the experimental visits. The measurements included: oxygen uptake, heart rate, rate of perceived exertion, muscle vasoreactivity during exercise; capillary glycaemia and lactataemia at several time points during exercise; continuous glucose monitoring data from the personal (used in daily life) device of the participants.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exercises were performed on a cycle ergometer (Excalibur Sport, Lode B.V.). Exercise began with a 3-min warm-up at 20% of maximum aerobic power (MAP) and ended with a 2-min active recovery at 20% of MAP. The high-intensity interval exercise protocol consisted of ten 1-min intervals at 100% of MAP, each interspersed with 1-min of passive recovery. For the postprandial state, exercise began 1.5 hours after the start of lunch and the corresponding meal-related bolus/rapid-acting insulin (i.e., in the early afternoon).
Exercises were performed on a cycle ergometer (Excalibur Sport, Lode B.V.). Exercise began with a 3-min warm-up at 20% of maximum aerobic power (MAP) and ended with a 2-min active recovery at 20% of MAP. The high-intensity interval exercise protocol consisted of ten 1-min intervals at 100% of MAP, each interspersed with 1-min of passive recovery. For the postabsorptive state, exercise began 5 hours after the start of lunch (i.e., in the late afternoon).
Exercises were performed on a cycle ergometer (Excalibur Sport, Lode B.V.). Exercise began with a 3-min warm-up at 20% of maximum aerobic power (MAP) and ended with a 2-min active recovery at 20% of MAP. The moderate-intensity continuous exercise protocol consisted of continuous exercise at 50% of MAP for 20 minutes. For the postprandial state, exercise began 1.5 hours after the start of lunch and the corresponding meal-related bolus/rapid-acting insulin (i.e., in the early afternoon).
Exercises were performed on a cycle ergometer (Excalibur Sport, Lode B.V.). Exercise began with a 3-min warm-up at 20% of MAP and ended with a 2-min active recovery at 20% of maximum aerobic power (MAP). The CONT protocol consisted of continuous exercise at 50% of MAP for 20 minutes. For the postabsorptive state, exercise began 5 hours after the start of lunch (i.e., in the late afternoon).
Time frame: At rest before exercise, then at 10 and 20 min of exercise, at 2 min of active recovery post-exercise, and at 10 min of passive recovery post-exercise.
Blood glucose meter
Time frame: The 24 hours before and the 24 hours after each visit
Continuous Glucose Monitoring system used by the participant in daily life
Time frame: At rest before exercise, then at 10 and 20 min of exercise, at 2 min of active recovery post-exercise, and at 10 min of passive recovery post-exercise.
Measured using the Lactate Scout device.
Time frame: During a 5-min rest before exercise, a 3-min warm-up, 20-min of exercise, a 2-min active recovery post-exercise, and a 10-min passive recovery post-exercise.
Measured with a mask and a Vynthus CPX, Vyaire Medical
Time frame: At rest before the exercise, and then at 5-min, 10-min, 15-min and 20-min of exercise, at 2-min active recovery post-exercise and at 5 and 10-min passive recovery post-exercise.
Rate of Perveived Exertion from the Borg Scale (6 to 20 scale)
Time frame: During a 5-min rest before exercise, a 3-min warm-up, 20-min of exercise, a 2-min active recovery post-exercise, and a 5-min passive recovery post-exercise.
Measured with Near infrared spectroscopy (Artinis, PortaLite)
Time frame: During a 5-min rest before exercise, a 3-min warm-up, 20-min of exercise, a 2-min active recovery post-exercise, and a 10-min passive recovery post-exercise.
Measured with Polar V800.
Time frame: At the end of 10-min passive recovery post-exercise.
Physical activity enjoyment scale (PACES) 18 items rated on a 7-point Likert scale.
Universite du Littoral Cote d'Opale
Other
The Protective Role of High-intensity Interval Exercise Compared With Continuous Moderate Exercise on Glycemia Decrease is More Relevant in Postabsorptive vs. Postprandial State in Adults With Type 1 Diabetes
Acronym: Interdiab 1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05262387
Autoimmune Diseases, Behavior
Toronto, Ontario, Canada
View Trial DetailsNCT02660242
Autoimmune Diseases, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT07711275
Autoimmune Diseases, Diabetes Mellitus
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05742243
Autoimmune Diseases, Diabetes Mellitus
Westmead, New South Wales, Australia
View Trial Details